Drug-metabolizing enzymes in rat liver myofibroblasts

Biochemical Pharmacology

Volumn 55, Issue 5, 1998, Pages 703-708

  Peterson, Theresa C ^a,b   Rowden, Geoffrey ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Aryl hydrocarbon hydroxylase; Ethoxyresorufin O deethylase; Methoxyresorufin O demethylase; Myofibroblast

Indexed keywords

BENZ[A]ANTHRACENE; CYTOCHROME P450 ISOENZYME; ETHOXYRESORUFIN DEETHYLASE; METHOXYRESORUFIN DEMETHYLASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; STELLATE CELL;

EID: 0032032882     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00593-5     Document Type: Article

References (24)

1. 1. Peterson TC, Malatjalian DA and Williams CN, Monocyte-aryl hydrocarbon hydroxylase (AHH) activity mimics Kupffer cell and hepatocyte AHH activity in an animal model of liver disease. Can J Physiol Pharmacol 69: 1797-1803, 1991.
2. 2. Peterson TC, Interleukiri-1, platelet derived growth factor, free radicals and monocyte aryl hydrocarbon hydroxylase activity in liver disease: Role of cell communication. Biochem Pharmacol 43: 1163-1166, 1992.
3. 3. Pinzani M, Novel insights into the biology and physiology of the Ito cell. Pharmacol Ther 66: 387-412, 1995.
4. 4. Grant MH, Duthie SJ, Gray AG and Burke MD, Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line. Biochem Pharmacol 37: 4111-4116, 1988.
5. 5. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T and Mayer RT, Ethoxy-, pentoxy-, and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34: 3337-3345, 1985.
6. 6. Roberts CEA, Xie ZW, Yang S and Lipa J, Inducibility of enzyme activities associated with the cytochrome P-450 1A family, ethoxyresorufin O-deethylase and methoxyresorufin O-demethylase in human hepatocyte lines derived from normal liver tissue. Drug Metab Dispos 21: 56-61, 1993.
7. 7. Putnam AD and Peterson TC, Effect of aging and other factors on monocyte AHH activity. Mech Ageing Dev 60: 61-74, 1991.
8. 8. Peterson TC, Monocyte aryl hydrocarbon hydroxylase activity and mortality. Clin Invest Med 14: 72-76, 1991.
9. 9. Peterson TC, Drug-metabolizing enzymes in rat, mouse, pig and human macrophages and the effect of phagocytic activation. Biochem Pharmacol 36: 3911-3916, 1987.
10. 10. Cantrell E and Bresnick E, Benzpyrene hydroxylase activity in isolated parenchymal and non-parenchymal cells of rat liver. J Cell Biol 52: 316-321, 1972.
11. 11. Burke MD, Thompson S, Weaver RJ, Wolf CR and Mayer RT, Cytochrome P450 specificities of alkoxyresorufin O-dealkylation on human and rat liver. Biochem Pharmacol 48: 923-936, 1994.
12. 12. Isbrucker RA and Peterson TC, Effect of PDGF, pentoxifylline and metabolite-1 on collagen production in porcine hepatic stellate cells. Hepatology 22: 280A, 1995.
13. 13. Peterson TC, Isbrucker R and Hooper M, In vitro effect of platelet derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 28: 259-270, 1994.
14. 14. Friedman SL, The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 24: 1828-1835, 1993.
15. 15. Peterson TC, Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptors. Biochem Pharmacol 52: 597-602, 1996.
16. 16. Peterson TC and Neumeister M, Effect of pentoxifylline in rat and swine models of hepatic fibrosis: Role of fibroproliferation in its mechanism. Immunopharmacology 31: 183-193, 1996.
17. 17. Peterson TC and Williams CN, Depression of peripheral blood monocyte AHH activity in patients with liver disease: Possible involvement of macrophage factors. Hepatology 7: 333-337, 1987.
18. 18. Peterson TC, Pentoxifylline prevents fibrosis in an animal model and inhibits platelet derived growth factor driven proliferation of fibroblasts. Hepatology 17: 486-493, 1993.
19. 19. Mauro VF, Mauro LS and Hageman JH, Comparison of pentoxifylline pharmacokinetics between smokers and non-smokers. J Clin Pharmacol 32: 1054-1058, 1992.
20. 20. Fuhr U, Anders E, Mahan G, Sorgel F and Staib A, Inhibitory potency of quinolone antibacterial agents against cytochrome P-450 1A2 activity in vivo and in vitro. Antimicrob Agents Chemother 36: 942-948, 1992.
21. PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696-7700, 1989.
22. 22. Hodgson PD and Peterson TC, Effect of pentoxifylline in a heterologous serum model of fibrosis in the rat. Hepatology 22: 429A, 1995.
23. 23. Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW and Bursten S, Protection from endotoxic shock in mice by pharmacologie inhibition of phosphatidic acid. Proc Natl Acad Sci USA 91: 3857-3861, 1994.
24. 24. Reims A, Poirier J, Lecoz F, Midavaine M, Lecocq B, Grange J, Poupon R, Cheymol G and Jaillon P, Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 47: 354-359, 1990.